Skip to Main Content

File this under “three strikes and you’re out!”

Twice last fall, the House Committee on Oversight and Government Reform asked Mylan Pharmaceuticals to submit documents about EpiPen pricing, but to date, the company has provided precious few. So last Friday, the committee warned Mylan attorneys that, if the company does not comply, a subpoena may be issued for Mylan execs to testify and produce the documents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • gag me why are they allowed to exclude the government settlement from their bonus calculation? This is nothing more than a catch up of a business expense or adjustment downward to revenue that should have taken place years ago.

Comments are closed.